{
    "clinical_study": {
        "@rank": "28673", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of gemcitabine and oxaliplatin in\n      treating patients who have locally advanced or metastatic pancreatic cancer."
        }, 
        "brief_title": "Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer", 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the objective tumor response rate in patients with locally advanced\n      or metastatic pancreatic carcinoma when treated with gemcitabine and oxaliplatin. II.\n      Determine the tolerablility and clinical benefit of this regimen in these patients. III.\n      Evaluate the progression free survival and the overall survival of these patients when\n      treated with this regimen.\n\n      OUTLINE: This is a multicenter study. Patients receive gemcitabine IV on day 1 over 1.5\n      hours and oxaliplatin IV over 2 hours on day 2. Treatment continues every 2 weeks in the\n      absence of disease progression or unacceptable toxicity. Patients with locally advanced\n      disease receive 6-8 courses and then may undergo surgery, radiotherapy, and/or additional\n      chemotherapy.\n\n      PROJECTED ACCRUAL: A total of 66 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic or locally\n        advanced unresectable adenocarcinoma of the pancreas Measurable disease At least 2 cm in\n        diameter No known brain metastases\n\n        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: ECOG 0-2 OR Karnofsky 60-100%\n        Life expectancy: Greater than 12 weeks Hematopoietic: Absolute neutrophil count at least\n        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times\n        upper limit of normal (ULN) Alkaline phosphatase no greater than 5 times ULN Renal:\n        Creatinine no greater than 1.5 times ULN Cardiovascular: Adequate cardiac function\n        Pulmonary: Adequate respiratory function Other: Not pregnant or nursing Fertile patients\n        must use effective contraception No sensitive neuropathy No other active malignancy No\n        uncontrolled hypercalcemia No significant medical or psychiatric condition that would\n        preclude study No psychological, familial, sociological, or geographical condition that\n        would preclude study\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior\n        chemotherapy Endocrine therapy: No concurrent corticosteroid use except as antiemetic\n        Radiotherapy: No prior radiotherapy Surgery: Not specified Other: No other concurrent\n        investigational drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "August 3, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006117", 
            "org_study_id": "CDR0000068130", 
            "secondary_id": [
                "FRE-GERCOR-GEMOX-D99-2", 
                "EU-20027"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "gemcitabine hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "oxaliplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Oxaliplatin"
            ]
        }, 
        "keyword": [
            "stage III pancreatic cancer", 
            "stage IV pancreatic cancer", 
            "adenocarcinoma of the pancreas"
        ], 
        "lastchanged_date": "October 29, 2009", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/FRE-GERCOR-GEMOX-D99-2"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49036"
                    }, 
                    "name": "Centre Paul Papin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Argenteuil", 
                        "country": "France", 
                        "zip": "95107"
                    }, 
                    "name": "Centre Hospitalier Victor Dupouy"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clichy", 
                        "country": "France", 
                        "zip": "92118"
                    }, 
                    "name": "Hopital Beaujon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21000"
                    }, 
                    "name": "Hopital Drevon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69008"
                    }, 
                    "name": "Clinique Saint Jean"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neuilly Sur Seine", 
                        "country": "France", 
                        "zip": "F-92202"
                    }, 
                    "name": "American Hospital of Paris"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75571"
                    }, 
                    "name": "Hopital Saint Antoine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75970"
                    }, 
                    "name": "Hopital Tenon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France", 
                        "zip": "F-51100"
                    }, 
                    "name": "Polyclinique De Courlancy"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France"
            ]
        }, 
        "official_title": "Phase II Study of Gemcitabine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Pancreatic Cancer", 
        "overall_official": {
            "affiliation": "Hopital Saint Antoine", 
            "last_name": "Christophe Louvet, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "17235048", 
            "citation": "Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007 Jan 20;25(3):326-31."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006117"
        }, 
        "results_reference": [
            {
                "PMID": "19435690", 
                "citation": "Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF, Mineur L, Artru P, Andr\u00e9 T, Louvet C. First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study. Bull Cancer. 2009 May;96(5):E18-22. Epub 2009 May 12."
            }, 
            {
                "PMID": "11896099", 
                "citation": "Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002 Mar 15;20(6):1512-8."
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2009"
    }, 
    "geocoordinates": {
        "American Hospital of Paris": "48.885 2.269", 
        "Centre Hospitalier Victor Dupouy": "48.947 2.249", 
        "Centre Paul Papin": "47.478 -0.563", 
        "Clinique Saint Jean": "45.764 4.836", 
        "Hopital Beaujon": "48.905 2.305", 
        "Hopital Drevon": "47.322 5.041", 
        "Hopital Saint Antoine": "48.857 2.352", 
        "Hopital Tenon": "48.857 2.352", 
        "Institut Jules Bordet": "50.85 4.352", 
        "Polyclinique De Courlancy": "49.258 4.032"
    }
}